Heron Therapeutics (HRTX) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Heron Therapeutics (HRTX) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 76.2% versus a loss of 85.2%. Over five years, HRTX leads with a -97.3% price change compared with -100.0% for TNXP. Heron Therapeutics is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size, while Tonix Pharmaceuticals is growing revenue faster (+29.8% vs +7.4%).
Heron Therapeutics converts more of its revenue into profit, with a net margin of -13.0% versus -946.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | TNXP |
|---|---|---|
| Share price | $0.2525 | $2.38 |
| Market cap | $48.04M | $46.25M |
| 1-day change | -4.39% | -6.67% |
| YTD return | -80.58% | -84.76% |
| 1-year return | -76.18% | -85.22% |
| 5-year return | -97.32% | -100.00% |
| EPS (TTM) | $-0.11 | $-12.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $154.90M | $13.11M |
| Revenue growth (YoY) | +7.36% | +29.85% |
| Net income (latest FY) | $-20.20M | $-124.02M |
| Gross margin | 73.31% | 49.34% |
| Operating margin | -1.64% | -959.05% |
| Net margin | -13.04% | -946.22% |
| 52-week high | $1.58 | $20.56 |
| 52-week low | $0.2479 | $2.30 |
| Distance from 52-week high | -84.02% | -88.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2672.28% | +1769.75% |
| Average volume | 4.56M | 838.83K |
| Shares outstanding | 190.27M | 19.43M |
| Employees | 128 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Heron Therapeutics is more profitable, keeping -13.0 cents of every revenue dollar as net income versus -946.2 cents for Tonix Pharmaceuticals.
- Tonix Pharmaceuticals grew revenue faster in its latest fiscal year (+29.85% vs +7.36%).
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
HRTX vs TNXP FAQ
Which is bigger, Heron Therapeutics or Tonix Pharmaceuticals?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $46.25M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, HRTX or TNXP?
HRTX returned -76.18% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.